Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 14Terminated 3Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Genitourinary 1

Conditions

Small Cell Lung Carcinoma 2Urinary Bladder Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × amrubicin × Clear all
NCT01904253 2024-09-05

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Taiho Oncology, Inc.

Phase 2 Terminated
18 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00286169 2022-04-12

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Sumitomo Pharma Co., Ltd.

Phase 3 Terminated
130 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01331824 2018-04-23

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
22 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡